Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) reported on 1/30/19 that patient six, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer ("... read more
Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) reported on 1/30/19 that patient six, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer ("... read more
Alector has filed for an IPO that will bring in approximately $180 million if options are exercised. The company is is focused on developing novel therapeutics that harness the brains immune... read more
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced on 1/28/19 that it is commencing a public offering of 8,000,000 Class A common shares. In addition, Kiniksa... read more
